CD8A and cancer: Additionally, BAT6026, a monoclonal antibody targeting OX40, has been shown to reduce Treg populations in the tumor microenvironment and activate effector T cells, particularly CD8+, suggesting its combination with immune checkpoint inhibitors, such as anti-PD-1, to generate durable responses in murine cancer models (112).